TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Shared Decision Making for Prostate Cancer Screening: a Practice-Based Randomized Controlled Trial
Brief Summary: The purpose of this study is to determine whether an intervention designed to help men share decisions about prostate cancer screening with their physician results in better decision making, more shared decisions, and changes in intended and actual screening rates.


Options:
A: Arm Label: Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Communication training and coaching | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Communication training and coaching; Assigned to Arm(s): Intervention
B: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Other: You Decide | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Other: Reducing Your Risks in the Crash | Intervention Type: OTHER; Name: You Decide; Assigned to Arm(s): 1 | Intervention Type: OTHER; Name: Reducing Your Risks in the Crash; Assigned to Arm(s): 2
C: Arm Label: Decision support; Type: EXPERIMENTAL; Interventions: Other: Feeding Options in Dementia Decision Aid | Arm Label: Control; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: OTHER; Name: Feeding Options in Dementia Decision Aid; Assigned to Arm(s): Decision support
D: Arm Label: Statin Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Statin Choice Decision Aid, Other: Usual care for antihyperglycemic medication | Arm Label: Diabetes Medication Choice Decision Aid; Type: ACTIVE_COMPARATOR; Interventions: Other: Diabetes Medication Choice Decision Aid, Other: Usual care for lipid therapy medication | Intervention Type: OTHER; Name: Diabetes Medication Choice Decision Aid; Assigned to Arm(s): Diabetes Medication Choice Decision Aid | Intervention Type: OTHER; Name: Statin Choice Decision Aid; Assigned to Arm(s): Statin Choice Decision Aid | Intervention Type: OTHER; Name: Usual care for lipid therapy medication; Assigned to Arm(s): Diabetes Medication Choice Decision Aid | Intervention Type: OTHER; Name: Usual care for antihyperglycemic medication; Assigned to Arm(s): Statin Choice Decision Aid

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study
Brief Summary: The purpose of this study is to examine the efficacy and safety of 26 weeks treatment with inhaled mannitol in subjects with cystic fibrosis. Previous studies have demonstrated improvements in lung function, mucociliary clearance, changes in physical properties of mucus, 24 hour sputum weight and quality of life. The results of this study are to further investigate and confirm these findings in addition to examine the effect on antibiotic use and chest infections. It is hypothesised that inhaled mannitol will have beneficial effects compared to a control treatment. An open label phase of 26 weeks duration will follow the blinded 26 week phase. During the open label phase all subjects will receive active treatment.


Options:
A: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: inhaled mannitol | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: inhaled mannitol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): B
B: Arm Label: Group A; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group B; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group C; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group D; Type: N/A; Interventions: Behavioral: Qualitative Interview | Arm Label: Group E; Type: N/A; Interventions: Behavioral: Qualitative Interview | Intervention Type: BEHAVIORAL; Name: Qualitative Interview; Assigned to Arm(s): Group A, Group B, Group C, Group D, Group E
C: Arm Label: Hypertonic Saline; Type: EXPERIMENTAL; Interventions: Drug: 6% Hypertonic Saline (HS), 4mL | Arm Label: Isotonic Saline; Type: ACTIVE_COMPARATOR; Interventions: Drug: 0.9% Isotonic Saline (IS), 4mL | Intervention Type: DRUG; Name: 6% Hypertonic Saline (HS), 4mL; Assigned to Arm(s): Hypertonic Saline | Intervention Type: DRUG; Name: 0.9% Isotonic Saline (IS), 4mL; Assigned to Arm(s): Isotonic Saline
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study
Brief Summary: The purpose of this study is to examine the efficacy and safety of 26 weeks treatment with inhaled mannitol in subjects with cystic fibrosis. Previous studies have demonstrated improvements in lung function, mucociliary clearance, changes in physical properties of mucus, 24 hour sputum weight and quality of life. The results of this study are to further investigate and confirm these findings in addition to examine the effect on antibiotic use and chest infections. It is hypothesised that inhaled mannitol will have beneficial effects compared to a control treatment. An open label phase of 26 weeks duration will follow the blinded 26 week phase. During the open label phase all subjects will receive active treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2
B: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: inhaled mannitol | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: inhaled mannitol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): B
C: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
D: Intervention Type: DRUG; Name: Inhaled mannitol; Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Long Term Administration of Inhaled Mannitol in Cystic Fibrosis- A Safety and Efficacy Study
Brief Summary: The purpose of this study is to examine the efficacy and safety of 26 weeks treatment with inhaled mannitol in subjects with cystic fibrosis. Previous studies have demonstrated improvements in lung function, mucociliary clearance, changes in physical properties of mucus, 24 hour sputum weight and quality of life. The results of this study are to further investigate and confirm these findings in addition to examine the effect on antibiotic use and chest infections. It is hypothesised that inhaled mannitol will have beneficial effects compared to a control treatment. An open label phase of 26 weeks duration will follow the blinded 26 week phase. During the open label phase all subjects will receive active treatment.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: mannitol | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Dornase alpha | Arm Label: 3; Type: OTHER; Interventions: Drug: mannitol + pulmozyme | Intervention Type: DRUG; Name: mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: mannitol + pulmozyme; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Dornase alpha; Assigned to Arm(s): 2
B: Arm Label: Placebo (pooled two times a day [BID]/three times a day [TID]); Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo two times a day (BID)/three times a day (TID) | Arm Label: AZLI (pooled two times a day [BID]/three times a day [TID]); Type: EXPERIMENTAL; Interventions: Drug: AZLI 75 mg two times a day (BID)/three times a day (TID) | Intervention Type: DRUG; Name: AZLI 75 mg two times a day (BID)/three times a day (TID); Assigned to Arm(s): AZLI (pooled two times a day [BID]/three times a day [TID]) | Intervention Type: DRUG; Name: Placebo two times a day (BID)/three times a day (TID); Assigned to Arm(s): Placebo (pooled two times a day [BID]/three times a day [TID])
C: Arm Label: A; Type: EXPERIMENTAL; Interventions: Drug: inhaled mannitol | Arm Label: B; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo comparator | Intervention Type: DRUG; Name: inhaled mannitol; Assigned to Arm(s): A | Intervention Type: DRUG; Name: Placebo comparator; Assigned to Arm(s): B
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Mannitol | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: Mannitol; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): 2

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)
Brief Summary: Prospective, randomized, controlled trial to test if post-operative administration of probiotics in HD patients will lead to a reduction in the occurrence of HAEC.


Options:
A: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: Bifidobacteria infantis; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Bifidobacteria infantis | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Bifidobacteria infantis; Assigned to Arm(s): Bifidobacteria infantis | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Saccharomyces boulardii; Type: EXPERIMENTAL; Interventions: Drug: Saccharomyces boulardii | Arm Label: control; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Saccharomyces boulardii; Assigned to Arm(s): Saccharomyces boulardii | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): control
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Probiotic Prophylaxis of Hirschprung's Disease Associated Enterocolitis (HAEC)
Brief Summary: Prospective, randomized, controlled trial to test if post-operative administration of probiotics in HD patients will lead to a reduction in the occurrence of HAEC.


Options:
A: Arm Label: "Milk" containing B. Lactis; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Probiotic supplementation | Arm Label: "Milk" containing placebo; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Milk containing placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Probiotic supplementation; Assigned to Arm(s): "Milk" containing B. Lactis | Intervention Type: DIETARY_SUPPLEMENT; Name: Milk containing placebo; Assigned to Arm(s): "Milk" containing placebo
B: Arm Label: Probiotics; Type: EXPERIMENTAL; Interventions: Drug: Bifico | Intervention Type: DRUG; Name: Bifico; Assigned to Arm(s): Probiotics
C: Arm Label: probiotic group; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Lactobacillus reuteri | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo | Intervention Type: DIETARY_SUPPLEMENT; Name: Lactobacillus reuteri; Assigned to Arm(s): probiotic group | Intervention Type: OTHER; Name: Placebo; Assigned to Arm(s): Placebo
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: VSL#3 | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: VSL#3; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: The Importance of Increasing Intake of Essential Fatty Acids During Complementary Feeding on Infant Growth and Body Composition, Intestinal Health, Immune Function and Risk Markers for Later Metabolic Complications.
Brief Summary: The objective of this intervention study is to examine the effect of n-3 LCPUFA on growth and body composition, intestinal health and microbiotic composition, immune function and risk markers for later diseases in 9-18 months old infants and toddlers.


Options:
A: Arm Label: Fish Oil; Type: EXPERIMENTAL; Interventions: Dietary Supplement: Fish Oil | Arm Label: Sunflower oil; Type: PLACEBO_COMPARATOR; Interventions: Dietary Supplement: Sunflower Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Fish Oil; Assigned to Arm(s): Fish Oil | Intervention Type: DIETARY_SUPPLEMENT; Name: Sunflower Oil; Assigned to Arm(s): Sunflower oil
B: Arm Label: DHA capsules; Type: EXPERIMENTAL; Interventions: Drug: DHA | Arm Label: Placebo capsules; Type: PLACEBO_COMPARATOR; Interventions: Other: Placebo capsule | Intervention Type: DRUG; Name: DHA; Assigned to Arm(s): DHA capsules | Intervention Type: OTHER; Name: Placebo capsule; Assigned to Arm(s): Placebo capsules
C: Arm Label: Commercially available infant formula A; Type: EXPERIMENTAL; Interventions: Other: Infant Formula milk based | Arm Label: Commercially available infant formula B; Type: ACTIVE_COMPARATOR; Interventions: Other: Infant formula milk based | Intervention Type: OTHER; Name: Infant Formula milk based; Assigned to Arm(s): Commercially available infant formula A | Intervention Type: OTHER; Name: Infant formula milk based; Assigned to Arm(s): Commercially available infant formula B
D: Arm Label: Marinol; Type: ACTIVE_COMPARATOR; Interventions: Dietary Supplement: Marinol D-40 | Arm Label: Nutrition counseling; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: DIETARY_SUPPLEMENT; Name: Marinol D-40; Assigned to Arm(s): Marinol

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Translating Research Into the Prevention of Diabetes Mellitus (TRIP DM)
Brief Summary: The Healthy Living Partnership to Prevent Diabetes (HELP PD) is a 300-participant randomized trial designed to test the effectiveness of a lay-health counselor led community-based diabetes prevention program in reducing blood glucose in people at risk for developing diabetes mellitus.


Options:
A: Arm Label: Lifestyle; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based Lifestyle Intervention (Phases 1 and 2), Behavioral: Self-Directed Maintenance (Phase 3), Behavioral: Extended Group Maintenance (Phase 3) | Arm Label: Comparison; Type: OTHER; Interventions: Other: Individual Education Program (All Phases) | Intervention Type: BEHAVIORAL; Name: Group-Based Lifestyle Intervention (Phases 1 and 2); Assigned to Arm(s): Lifestyle | Intervention Type: OTHER; Name: Individual Education Program (All Phases); Assigned to Arm(s): Comparison | Intervention Type: BEHAVIORAL; Name: Self-Directed Maintenance (Phase 3); Assigned to Arm(s): Lifestyle | Intervention Type: BEHAVIORAL; Name: Extended Group Maintenance (Phase 3); Assigned to Arm(s): Lifestyle
B: Arm Label: High Fiber Diet; Type: EXPERIMENTAL; Interventions: Behavioral: Dietary Intervention | Arm Label: AHA Diet; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Dietary Intervention | Intervention Type: BEHAVIORAL; Name: Dietary Intervention; Assigned to Arm(s): AHA Diet, High Fiber Diet
C: Arm Label: Lifestyle & Behavioral Change Program; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle & Behavioral Change Program | Arm Label: Structured Education Program; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Structured Education Program | Intervention Type: BEHAVIORAL; Name: Lifestyle & Behavioral Change Program; Assigned to Arm(s): Lifestyle & Behavioral Change Program | Intervention Type: BEHAVIORAL; Name: Structured Education Program; Assigned to Arm(s): Structured Education Program
D: Intervention Type: BEHAVIORAL; Name: dietary intervention; Assigned to Arm(s): N/A

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Translating Research Into the Prevention of Diabetes Mellitus (TRIP DM)
Brief Summary: The Healthy Living Partnership to Prevent Diabetes (HELP PD) is a 300-participant randomized trial designed to test the effectiveness of a lay-health counselor led community-based diabetes prevention program in reducing blood glucose in people at risk for developing diabetes mellitus.


Options:
A: Arm Label: Lifestyle; Type: EXPERIMENTAL; Interventions: Behavioral: Group-Based Lifestyle Intervention (Phases 1 and 2), Behavioral: Self-Directed Maintenance (Phase 3), Behavioral: Extended Group Maintenance (Phase 3) | Arm Label: Comparison; Type: OTHER; Interventions: Other: Individual Education Program (All Phases) | Intervention Type: BEHAVIORAL; Name: Group-Based Lifestyle Intervention (Phases 1 and 2); Assigned to Arm(s): Lifestyle | Intervention Type: OTHER; Name: Individual Education Program (All Phases); Assigned to Arm(s): Comparison | Intervention Type: BEHAVIORAL; Name: Self-Directed Maintenance (Phase 3); Assigned to Arm(s): Lifestyle | Intervention Type: BEHAVIORAL; Name: Extended Group Maintenance (Phase 3); Assigned to Arm(s): Lifestyle
B: Arm Label: Lifestyle coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Watchers | Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight Watchers, Behavioral: National Diabetes Education Program | Intervention Type: BEHAVIORAL; Name: Weight Watchers; Assigned to Arm(s): Lifestyle coaching, Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: National Diabetes Education Program; Assigned to Arm(s): Lifestyle counseling
C: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Control arm (usual care/standard care arm) | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: Experimental | Intervention Type: BEHAVIORAL; Name: Experimental; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: Control arm (usual care/standard care arm); Assigned to Arm(s): 2
D: Arm Label: Usual Care Only; Type: ACTIVE_COMPARATOR; Interventions: Other: Usual Care Only | Arm Label: Vida Sana; Type: EXPERIMENTAL; Interventions: Behavioral: Vida Sana | Intervention Type: BEHAVIORAL; Name: Vida Sana; Assigned to Arm(s): Vida Sana | Intervention Type: OTHER; Name: Usual Care Only; Assigned to Arm(s): Usual Care Only

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma
Brief Summary: Primary objective: Comparison of independently assessed progression free survival (PFS) in subjects administered Bevacizumab + Temsirolimus vs. those administered Bevacizumab + Interferon-Alfa. Secondary objectives: safety, Investigator assessed PFS, objective response rate (independently assessed), and overall survival.


Options:
A: Arm Label: bevacizumab, RAD001 (everolimus); Type: EXPERIMENTAL; Interventions: Drug: RAD001(everolimus), Drug: bevacizumab | Arm Label: bevacizumab, interferon alfa-2a (IFN); Type: ACTIVE_COMPARATOR; Interventions: Drug: interferon alfa-2a, Drug: bevacizumab | Intervention Type: DRUG; Name: RAD001(everolimus); Assigned to Arm(s): bevacizumab, RAD001 (everolimus) | Intervention Type: DRUG; Name: interferon alfa-2a; Assigned to Arm(s): bevacizumab, interferon alfa-2a (IFN) | Intervention Type: DRUG; Name: bevacizumab; Assigned to Arm(s): bevacizumab, RAD001 (everolimus), bevacizumab, interferon alfa-2a (IFN)
B: Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Interferon-alfa | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: SU011248 | Intervention Type: DRUG; Name: Interferon-alfa; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: SU011248; Assigned to Arm(s): 1
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Bevacizumab, Drug: Temsirolimus | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Bevacizumab, Drug: Interferon-Alfa 9MU | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Temsirolimus; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Bevacizumab; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Interferon-Alfa 9MU; Assigned to Arm(s): 2
D: Arm Label: Savolitinib; Type: EXPERIMENTAL; Interventions: Drug: Savolitinib | Arm Label: Sunitinib; Type: ACTIVE_COMPARATOR; Interventions: Drug: Sunitinib | Intervention Type: DRUG; Name: Savolitinib; Assigned to Arm(s): Savolitinib | Intervention Type: DRUG; Name: Sunitinib; Assigned to Arm(s): Sunitinib

Answer: C